N-linked glycosylation of GETV envelope proteins affect viral infection and pathogenicity Authors: Hui Meng, Tianyi Wang, Chunxiao Mou, Yanmei Huang, Zhenhai Chen Published: 2026 ABSTRACT ABSTRACTGetah virus (GETV) is an emerging mosquito-borne pathogen with a broad host range, posing a significant threat to livestock and public health. Although putative N-linked glycosylation sites on its envelope proteins have been reported, their precise functional roles remain uncharacterized. In this study, tunicamycin inhibition assays demonstrated that GETV replication depends on the host glycosylation machinery. Enzymatic dissection revealed that the envelope proteins E1 and E2 carry complex-type N-linked glycans, which are critical for infectivity. By constructing envelope protein N-linked glycosylation site mutants, it was revealed that the E1-N141 site influences viral entry, whereas the E2-N262 site was critical for both viral adsorption and internalization. Mutations at all envelope protein N-linked glycosylation sites impaired the infectivity of progeny virions, resulting in delayed replication kinetics and significantly reduced viral titers. In ICR mice model, all mutants showed attenuated pathogenicity, with the E2-N200 mutation conferring the most substantial reduction in virulence. Notably, despite reduced virulence, some mutants (E1-N141A and E2-N200A/N262A) elicited neutralizing antibody responses stronger than those induced by wild-type virus and provided complete protection against subsequent challenge with wild-type GETV. These findings highlight the critical role of envelope protein glycosylation in GETV infectivity and pathogenesis, providing a molecular basis for rational vaccine design.KEYWORDS: Getah virus, envelope protein, N-linked glycosylation, viral replication, pathogenicity, neutralizing antibody Introduction Getah virus (GETV) is a mosquito-borne positive-sense RNA virus belonging to the genus Alphavirus within the family Togaviridae [1,2]. Since its initial isolation in Malaysia in 1955, GETV has been detected in numerous countries across Asia, with natural hosts including livestock such as pigs, horses, blue foxes and cattle, as well as wild animals [3–7]. In recent years, GETV outbreaks in swine populations have drawn significant attention [8,9]. Infection in sows can cause reproductive disorders such as abortions and stillbirths, while piglets may exhibit diarrhea, neurological symptoms, and mortality, leading to substantial economic losses in the swine industry [10,11]. The GETV genome encodes several structural proteins, including the capsid (Cap) protein, E3, E2, 6K, and E1. Among these, the envelope protein E1 and E2 play a central role in viral entry into host cells and the induction of antibody responses, serving as key determinants of viral infectivity and pathogenicity. N-linked glycosylation of viral proteins is a widespread and highly conserved post-translational modification with multifaceted regulatory roles in their biological functions. Extensive studies have shown that glycosylation of envelope proteins is critical for proper folding, conformational stability, intracellular trafficking, and virion assembly [12,13]. More importantly, these sugar chains can act as a “sugar shield” to physically mask the antigenic epitopes on the surface of the virus, helping the virus evade the neutralizing antibody response of the host. This is one of the key mechanisms by which the virus achieves immune evasion [14,15]. At present, there are various studies on the function of N-linked glycosylation modification of the alphavirus envelope protein. For instance, in the Ross River virus (RRV), the N-linked glycosylation of the envelope proteins enhances the skin immune response by promoting the induction of type I interferons [16]. In the Sindbis virus (SINV), the lack of N-linked glycosylation in the E1 protein impairs intracellular viral replication. While lack of N-linked glycosylation in the E2 protein can enhance the binding of the virus to heparin, resulting in an increased virulence [17]. Similarly, N-linked glycosylation site mutants of salmonid alphavirus (SAV) envelope proteins exhibit reduced cytopathic effects and lower yields of infectious virions [18]. In Chikungunya virus (CHIKV), N-linked glycosylation of envelope proteins significantly enhances cell-mediated immune responses [19]. It is worth noting that although several studies have predicted the N-linked glycosylation sites of the GETV envelope protein and visualized the density of sugar chains at these sites using cryo-electron microscopy [2,20,21], the specific function of N-linked glycosylation modifications in GETV replication remains unknown. Therefore, clarifying the roles of these sites in viral replication, pathogenicity, and immunogenicity is a key issue that needs to be addressed urgently. To address these questions, this study aims to elucidate the role of N-linked glycosylation during the GETV infection. Using chemical inhibitors and site-directed mutagenesis, we identified functional glycosylation sites on the E1 and E2 proteins and dissected their effects on viral adsorption, internalization, replication, and progeny virus production. Furthermore, using animal models, we evaluated the impact of glycosylation loss on viral virulence and immunogenicity. Our findings not only deepen the understanding of GETV pathogenesis at the molecular level, but also provide a critical foundation for the development of novel attenuated vaccine. Materials and methods Cell lines, viruses and antibodies Baby Hamster Kidney (BHK-21) and Swine Testis (ST) cells were purchased from China Center for Type Culture Collection and maintained in Dulbecco’s modified Eagle’s medium (Gibco, USA) supplemented with 10% fetal bovine serum (Lonsera, China). The cells were incubated at 37°C in an atmosphere containing 5% carbon dioxide. For infected cells, a maintenance medium with 2% FBS was used. GETV HuN1 strain (GenBank number: MF741771.1) were kept at our laboratory. Mouse anti-GETV Cap protein, E1 protein and E2 protein monoclonal antibodies were produced in our laboratory. Alexa Fluor 488-conjugated goat anti-mouse were purchased from AmyJet Scientific (China). Mouse anti-GAPDH antibody and HRP-conjugated Goat Anti-Mouse were purchased from Proteintech (China). Cytotoxicity assay The different concentrations of tunicamycin (MCE, USA) were added to the cell culture medium and the cells were incubated for 24 hours. The cytotoxicity was detected using the Cell Counting Kit-8 (NCM, China) following the manufacturer’s instructions. An equal volume of DMSO was used as the control. Prediction and analysis of GETV membrane protein structure and glycosylation sites The N-linked glycation sites of GETV membrane proteins (E1, E2 and E3) were predicted using the online NetNGlyc server (https://services.healthtech.dtu.dk/services/NetNGlyc-1.0/). The structure of membrane protein was predicted using the online SWISS MODEL server (https://swissmodel.expasy.org). The membrane protein sequences of the 10 prevalent genotypes were obtained from GenBank of NCBI. The distribution of the N-glycosylation site in membrane proteins of the 10 prevalent genotypes was analyzed using the online Sequence Alignment (https://www.genome.jp/tools-bin/clustalw, https://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi). Construction and recovery of recombinant GETV In order to produce envelope protein N-linked glycosylation site mutant plasmids, specific primers containing mutations in glycosylation sites were designed and listed in Table S1 (Supplemental material 3). The mutation fragments were amplified by overlap PCR. Then these fragments were cloned into pAC-GETV vector respectively to produce different N-glycosylation site mutant plasmids named as pAC-GETV(E1-N141A), pAC-GETV(E2-N200A), pAC-GETV (E2-N262A) and pAC-GETV (E2-N200A/ N262A). These infectious clone plasmids were transfected into BHK-21 cells. When approximately 90% of the cells exhibited cytopathic effect (CPE), the supernatant was harvested and inoculated into ST cells. After three serial passages, the supernatant was collected at 24 hpi for subsequent analysis. These N-linked glycosylation site mutant virus were named as GETV (E1-N141A), GETV (E2-N200A), GETV (E2-N262A) and GETV (E2-N200A/ N262A). Indirect immunofluorescence assay (IFA) Cells were seeded in cell culture plates for 12 h and then infected with WT-GETV or N-linked glycosylation mutants for 12 or 16 hours. The cells were fixed with 4% paraformaldehyde at room temperature for 15 min. Then, cells were permeabilized with 0.01% Triton X-100 and blocked with 2% bovine serum albumin at room temperature for 30 min, followed by overnight incubation at 4°C with mouse anti-GETV Cap protein monoclonal antibody. After washing three times with PBS, the cells were incubated with Alexa Fluor 488-conjugated goat anti-mouse at room temperature for 1 h. Finally, cells were stained with 4,6-diamidino-2-phenylindole (DAPI) for 10 min. After washing with PBS, images were captured using a fluorescence microscope. Western blot analysis ST cells were seeded onto 6-well plate for 12 h and then infected with WT-GETV or N-linked glycosylation mutants. Firstly, the cells were lysed at 0, 12 and 24 hpi with radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime, China) on ice for 30 min, and were boiled at 95°C for 5 min. Then the cell lysate was separated by SDS-PAGE, and transferred to a nitrocellulose membrane. The membranes were blocked in TBST containing 5% nonfat milk for 2 h, and then incubated with the corresponding primary antibodies overnight at 4°C. After washing three times with TBST, membranes were incubated with HRP-conjugated Goat Anti-Mouse at room temperature for 1 h. Finally, the membranes were visualized using NcmECL Ultra (NCM, China) by a chemiluminescence imaging system (Tanon). Virus titration by TCID50 method ST cells on 6-well plates were infected with WT-GETV or N-linked glycosylation mutants and harvested at different time points post-infection (6, 12, 24, 36 and 48 hpi). ST cells on 96-well plates were infected with 10-fold serial dilutions from 101 to109. Each dilution had four replicates. At three days post-inoculation, the number of infected wells was counted, and the 50% tissue culture infection dose (TCID50) of each sample was determined by using the Karber method. Plaque assays ST cells were seeded onto a 6-well plate and cultured until a confluent monolayer was formed. Cells were incubated with culture medium containing GETV for 2 h. A mixture of 2% low melting point agarose and DMEM containing 1% penicillin-streptomycin and 2% FBS in a 1:1 ratio was used to cover the cells. The cells were then incubated at 37°C for 36 h. Next, the cells were fixed and stained with Crystal Violet Staining Solution (1% crystal violet, 20% ethanol, 0.85% NaCl, and 5% methanol) for 2 h. The low melting point agarose overlay was removed, and the number of plaques in each well was counted. The plaque diameter was analyzed by the ImageJ software. Virus adsorption, internalization and replication ST cells were infected with WT-GETV or N-linked glycosylation mutants at an MOI of 1. For virus adsorption, the supernatants were removed after the infected cells were incubated on ice for 1 h. For virus internalization, the infected cells were cultured for 1 h on ice. After three washes, the cells were cultured for another 1 h at 37°C. For virus replication, the infected cells were cultured for 4 h, 8 h, 12 h at 37°C. The infected cells were washed three times to eliminate the unbound virus and lysed with TRIzol reagent (Vazyme, China) for viral RNA extraction. Quantitative real-time PCR (RT-qPCR) ST cells were seeded onto 6-well plate for 12 h and then infected with WT-GETV or N-linked glycosylation mutants. RNA were extracted at 0, 4, 8, 12 and 24 hpi by using RNA-easy Isolation Reagent (R701) (Vazyme, China)and reversely transcribed into cDNA using a Hifair® III 1st Strand cDNA Synthesis SuperMix (Yeasen, China) following the manufacturer’s protocol. 20 µL qPCR reaction mixture contained 10 µL 2× One-Step SYBR Green mix, 7.2 µL RNase-free ddH2O, 0.4 µL (10 µM) of each primer, and 2 µL RNA. Amplification was performed as follows: 95°C for 3 min; 95°C for 30 s; 40 cycles at 95°C for 10 s and 60°C for 30. The number of Cap gene copies is used to represent the replication level of the virus. The β-Actin was used as an internal control. The data were analyzed using the cycle threshold (2− ∆∆ Ct) method. The primers used for RT-qPCR are listed in Table S2 (Supplemental material 3). Mouse experiments To assess the pathogenicity of GETV and N-linked glycosylation mutants, forty-eight 3-day-old ICR suckling mice were randomly divided into 6 groups (8 mice in each group, 4 mice were used to measure body weight and survival rate, and 4 mice were used to collect tissue samples.) with cages randomly placed, and they were housed with their biological mothers. The suckling mice (n = 4 per group) were subcutaneously inoculated with 30 μL of DMEM containing 1 × 106 TCID50 of WT-GETV, GETV (E1-N141A), GETV (E2-N200A), GETV (E2-N262A) or GETV (E2-N200A/ N262A); the control group received DMEM. Body weight and mortality were performed daily for 10 days after infection. In addition, the suckling mice (n = 4 per group) were euthanized at 4 days post injection (dpi), and the viral load in the brain, heart, kidney and hind limb was measured using RT-qPCR assay. To evaluate the immunogenicity of N-linked glycosylation mutants, thirty-six 3-week-old ICR mice were randomly divided into 6 groups (6 mice in each group) with cages randomly placed. The mice were subcutaneously inoculated with 100 μL of DMEM containing 1 × 105 TCID50 WT-GETV or N-linked glycosylation mutants, and control mice received DMEM. Viral titer in serum collected were determined by TCID50 assays at 1 and 2 dpi. The blood samples were collected to detect the levels of neutralizing antibodies and specific IgG at 14 and 28 dpi. On day 30 post infection, the mice were challenged with a subcutaneous injection of 1 × 105 TCID50 of WT-GETV. Serum samples were collected to detect viral titer by TCID50 assays at 1 day and 2 days post challenge. To investigate whether N-linked glycans effectively shield neutralizing epitopes, the virus particles were treated with PNGase F to remove N-linked glycans from membrane proteins. Six 3-week-old mice were immunized subcutaneously with 105 TCID50 of deglycosylated GETV. The sera were collected at 14 dpi to evaluate neutralization efficacy against WT-GETV and other mutants. Neutralization tests Firstly, the serum was inactivated by incubating at 56°C for 30 min. Then the serum was serially diluted by 2-fold in DMEM containing 2% FBS. Each dilution was mixed with an equal volume of virus solution (100 TCID50/100 μL) and incubated at 37°C for 1 h. After incubation, 100 μL of the serum-virus mixture was added to each cell well, with 4 replicate wells for each dilution. The cell plates were then placed in a 37°C incubator for 48 h of further culture. The neutralizing titer of the serum antibodies was calculated according to the calculation formula (lg (neutralizing antibody titer) = L + d (S-0.5)). Enzyme-linked immunosorbent assay (ELISA) The pE3-E2-E1 recombinant protein (1 μg/mL) was immobilized onto the ELISA plate and coated at 4°C for 12 h. The coating solution was discarded, and the plate was washed three times with PBST. The recombinant protein was then incubated with ELISA blocking solution at 37°C for 1 h. After washing three times with PBST, diluted serum was added to the ELISA plate and incubated at 37°C for 1 h. The serum was discarded, and the plate was washed three times with PBST. HRP-labeled goat anti-mouse IgG antibody was added to the ELISA plate and incubated at 37°C for 1 h. The secondary antibody was discarded, and the plate was washed three times with PBST. Monocomponent TMB chromogenic solution was added to the ELISA plate and incubated at 37°C for 30 min, the reaction was terminated by adding the stop solution, and the absorbance at 450 nm (OD 450) was measured using an ELISA reader. Statistical analysis The statistical analysis was performed using GraphPad Prism 10.1.2. The data were presented as the mean ± standard deviation (SD) from three or more independent experiments and assessed using Tukey’s post hoc test. The asterisks in the figures denote significant differences, with *p < 0.05, **p < 0.01, ***p < 0.001and ****p < 0.0001. Results Tunicamycin effectively inhibited GETV infection N-linked glycosylation of viral proteins is critical for viral replication. To investigate whether this post-translational modification is involved in GETV infection, the infected cells were treated with tunicamycin, a specific inhibitor of N-linked glycosylation that blocks the formation of the N-glycan intermediate GlcNAc2-dolichol phosphate [20,21]. First, the cytotoxicity of tunicamycin was evaluated on ST cells. The cell viability remained nearly 100% at concentrations below 2 μg/mL Figure 1(A). Based on this, tunicamycin concentrations of 0.2 μg/mL and 2 μg/mL were selected for subsequent experiments. To examine the role of N-linked glycosylation in GETV infection, ST cells were pretreated with tunicamycin for 2 h and then infected with GETV. Viral replication was assessed using RT-qPCR, IFA, and Western blot analysis. Results showed that both transcription and expression levels of the Cap protein were significantly reduced in tunicamycin-treated cells Figure 1(B–F). Furthermore, viral growth was evaluated by measuring TCID50 and plaque formation. In ST cells pretreated with tunicamycin, GETV titers were significantly reduced by approximately 103.5-fold Figure 1(G–H). Collectively, these results demonstrate that tunicamycin attenuates GETV infectivity in a dose-dependent manner, indicating that N-linked glycosylation of envelope proteins plays an important role in GETV infection. Tunicamycin inhibits GETV replication in ST cells. ST cells were pretreated with tunicamycin (0, 0.2 or 2 μg/mL) for 2 h and then infected with GETV (MOI = 1) or mock-infected. Viral replication was assessed using multiple approaches (B-G). (A) Viability of ST cells after 24 h treatment with the indicated concentrations of tunicamycin. (B-D) Viral mRNA levels measured by RT-qPCR at 8, 16, and 24 hpi. (E) Immunofluorescence staining of GETV-infected ST cells at 12 hpi. Cells were labeled with an anti-Cap monoclonal antibody (green). Scale bars, 50 µm. (F) Western blot analysis of Cap protein expression at 12 hpi. (G) Viral titers determined by TCID50 assay at 24 hpi. (H) Plaque formation assay of GETV in ST cells pretreated with tunicamycin at 24 hpi. Data are mean ± SD of three independent experiments. Statistical significance was determined by Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. N-linked glycosylation of GETV envelope proteins is crucial for efficient viral adsorption and internalization N-linked glycans on viral proteins are classified into three types: high-mannose, hybrid, and complex [22]. PNGase F cleaves the amide bond between the innermost N-acetylglucosamine (GlcNAc) and asparagine residue, thereby removing all types of N-linked glycans, whereas Endo H specifically cleaves the chitobiose core of high-mannose and certain hybrid oligosaccharides in N-linked glycoproteins Figure 2(A). To determine whether GETV envelope proteins are modified by N-linked glycans, enzymatic removal of N-linked glycans was performed using PNGase F and Endo H. ST cells infected with GETV were treated with PNGase F or Endo H, and the electrophoretic mobility of E1 and E2 proteins was analyzed by Western blot. PNGase F treatment resulted in reduced molecular weights of both E1 and E2, while Endo H treatment did not alter their migration compared to untreated controls Figure 2(B–C), indicating that both proteins carry complex-type N-glycans. Subsequently, to explore the role of N-linked glycans on GETV envelope proteins during infection, the effect of N-linked glycosylation on viral infectivity was assessed by removing N-linked glycans from the surface of GETV particles using PNGase F. Following 12 h pretreatment at 37°C, ST cells were infected with treated or untreated virus at an MOI of 1. Viral adsorption, internalization, and replication were assessed by measuring the levels of viral mRNA and Capsid protein. Cells infected with deglycosylated virions showed reduced levels of viral gene transcription and protein expression Figure 2(D–I). Furthermore, growth curve analysis revealed that although both groups exhibited similar growth trends following infection, the deglycosylated virions showed a delayed replication kinetics. Specifically, the viral titer of wild-type virus peaked at 24 hpi, whereas that of the deglycosylated virus reached its peak at 30 hpi Figure 2(J). Together, these results demonstrate that GETV E1 and E2 envelope proteins are modified with complex-type N-glycans, which are critical for efficient viral attachment and internalization. N-linked glycans on the virion surface are critical for GETV replication. (A) schematic of the three main types of N-linked glycans on viral proteins and the cleavage sites of PNGase F and Endo H. (B-C) the ST cell samples infected with the GETV were treated with PNGase F and Endo H for 2 h at 37°C, respectively. The electrophoretic mobility of E1 protein and E2 protein were analyzed by Western blot using specific anti-E1 and anti-E2 antibodies. (D-J) ST cells were infected with PNGase F-treated or mock-treated GETV. (D-E) viral adsorption and internalization were quantified by RT-qPCR at 1 and 2 hpi, respectively. (F-H) early viral replication was assessed by RT-qPCR at 4, 8, and 12 hpi. (I) Cap protein expression analyzed by Western blot at 0, 12 and 24 hpi. (J) viral growth kinetics determined by TCID50 assay using supernatants harvested at the indicated time points (6, 12, 24, and 36 hpi). Data are mean ± SD of three independent experiments. Statistical significance was determined by Student’s t-test. *p < 0.05, **p < 0.01 and ***p < 0.001. Analysis of N-glycosylation sites in GETV envelope proteins Defining the precise amino acid residues that are N-glycosylated is critical for investigating the functional roles of this modification in viral proteins. First, the N-linked glycosylation sites on the two envelope proteins were predicted using the online server NetNGlyc1.0. The results found that E1 protein has one N-glycosylation modification site at the 141th amino acid position (N141) and E2 protein has two N-glycosylation modification sites at the 200th and 262th amino acid position (N200 and N262) (Figure S1 A-B). To visualize these glycosylation sites, the positions of these glycosylation sites were mapped onto the 3D model of the envelope protein trimer, and the N-glycosylation sites were highlighted in red. The 3D model revealed that all three sites are situated on the solvent-exposed surface of the proteins (Figure S1 C-D), supporting their accessibility for glycosylation and potential roles in host interactions. To evaluate the evolutionary conservation of these sites, the amino acid sequences of envelope protein of ten GETV strains that were reported in recent years were downloaded from the National Center for Biotechnology Information (NCBI), and the amino acid sequences of these virus strains were analyzed. The results showed that the N-glycosylation modification sites of different strains were highly conserved (Figure S1 E-F). Construction and identification of N-linked glycosylation site mutants To validate the predicted N-linked glycosylation sites and investigate the functional impact of glycosylation on viral replication and virulence, we generated a series of envelope protein glycosylation site mutants using the pAC-GETV infectious clone plasmid as the backbone. Specific asparagine residues at predicted sites were systematically replaced with alanine Figure 3(A). Following transfection of the mutant plasmids into BHK-21 cells, all groups exhibited typical cytopathic effects (CPE) Figure 3(B). Immunofluorescence assay (IFA) with anti-Cap antibodies confirmed successful viral protein expression in cells infected with each mutant virus Figure 3(C). After three serial blind passages in ST cells, sequencing analysis demonstrated stable genetic inheritance of all introduced mutations in the envelope proteins (Figure S2). These results confirm the successful rescue of all mutant viruses: GETV (E1-N141A), GETV (E2-N200A), GETV (E2-N262A), and GETV (E2-N200A/N262A). To verify the elimination of glycosylation at these sites, the electrophoretic mobility of envelope proteins was analyzed by Western blot. As expected, all mutants exhibited faster migration compared to wild-type virus. The E1 and E2 proteins from the GETV (E1-N141A) and GETV (E2-N200A/N262A) mutants, respectively, comigrated with their PNGase F-deglycosylated counterparts Figure 3(D–E). The E2-N200A/N262A double mutant showed a more pronounced band shift than either single mutant. These results demonstrated four N-linked glycosylation mutant viruses were successfully rescued. Construction and identification of N-linked glycosylation site mutated GETV. (A) Schematic of the infectious clone strategy for generating alanine-substitution (N→A) mutants at predicted N-glycosylation sites. (B) Cytopathic effect (CPE) observed in ST cells at 16 hpi with the indicated mutants. Scale bar, 50 µm. (C) Immunofluorescence assay confirming viral infection at 16 hpi, using an anti-Cap protein antibody (green). Scale bar, 500 µm. (D-E) ST cells were infected with WT-GETV or N-linked glycosylation-site mutants for 16 h. Western blot analysis of E1 (D) and E2 (E) proteins using specific antibodies to assess glycan loss via electrophoretic mobility shifts. The growth characteristics of N-linked glycosylation site mutants Previous studies have established that N-linked glycosylation is critical for the adsorption and internalization of many viruses. To determine whether this also applies to GETV, the adsorption and internalization capacity of N-linked glycosylation site mutants were evaluated by quantifying viral genomic RNA levels using RT-qPCR. During the adsorption assay, only cells infected with the GETV (E2-N262A) mutant exhibited a significant reduction in genomic RNA copies Figure 4(A). In the internalization assay, decreased genomic RNA levels were observed in cells infected with either the GETV (E1-N141A) or GETV (E2-N262A) mutant, whereas an increase was detected in samples infected with the GETV (E2-N200A) mutant. Interestingly, the GETV (E2-N200A/N262A) double mutant did not mirror the trend of either single mutant and showed no significant difference compared with WT-GETV Figure 4(B). To further assess the role of N-linked glycosylation in the GETV life cycle, we analyzed early replication kinetics of WT and glycosylation-deficient mutants by measuring viral genomic copies via RT-qPCR at 4, 8, and 12 hpi. The GETV (E1-N141A) and GETV (E2-N262A) mutants exhibited reduced genomic RNA replication levels Figure 4(C–E). In addition, one-step growth curve was generated by measuring viral titers at multiple time points to evaluate the production of infectious progeny virions. The glycosylation mutants displayed significant replication defects and delayed viral particle release. While WT-GETV reached its peak titer at 24 hpi, the mutant virus titer peaked at 36 hpi, with a maximum reduction of approximately 100-fold Figure 4(F). Overall, the mutation at the E2 N262 site significantly affects the virus’s adsorption, while the mutation at the E1 N141 site significantly influences the virus’s internalization. The decline in the efficiency of virus adsorption and internalization further led to a decrease in its replication level. These results indicated that N-linked glycosylation plays a crucial role in the early stage of viral infection. The influence of N-linked glycosylation during the GETV replication cycle. ST cells were infected (MOI = 1) with WT-GETV or the indicated N-linked glycosylation-site mutants. (A) The adsorption ability of GETV N-linked glycosylation mutants was detected by RT-qPCR at 1 hpi on ice. (B) The internalization ability of GETV N-linked glycosylation mutants was detected by RT-qPCR at 2 hpi. (C-E) The early replication ability of GETV N-linked glycosylation mutants was detected by RT-qPCR at 4, 8 and 12 hpi. (F) Multi-step growth kinetics were determined by TCID50 assay of supernatants collected at 6, 12, 24, 36 and 48 hpi. Data are presented as the mean ± SD from three independent experiments. Statistical significance was determined by Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. The pathogenicity of the N-linked glycosylation site mutants was significantly weakened To evaluate the pathogenicity of N-linked glycosylation site mutants, 3-day-old suckling mice were subcutaneously injected with 106 TCID50 of virus, as shown in Figure 5(A). The infected suckling mice were continuously observed for 10 days. During the entire monitoring period, differences in body weight gain and survival rates were observed among mice infected with the mutant viruses. Growth curve analysis revealed that mice infected with GETV (E1-N141A), GETV (E2-N200A), and GETV (E2-N200A/N262A) exhibited higher weight gain rates than those infected with WT-GETV, though their gains remained lower than those of the negative control group. Among these groups, mice in the WT-GETV group exhibited the slowest weight gain, whereas those in the GETV (E2-N200A) group showed a substantial increase in body weight Figure 5(B). The survival curve revealed that the survival rates in the GETV (E2-N200A) and GETV (E2-N200A/N262A) groups were both 75%, while the GETV (E1-N141A) group showed a survival rate of 50% Figure 5(C). In addition, viral genomic copies in various tissues were quantified by RT-qPCR at 2 days post-infection. The results demonstrated that the replication capacity of each N-linked glycosylation mutant was lower than that of WT-GETV in all tissues examined. Notably, all four glycosylation mutants exhibited a substantial reduction in genomic copies in the brain Figure 5(D–G). These data indicated that N-linked glycosylation at different amino acid sites influences viral pathogenicity to varying degrees, with the E2-N200A mutation conferring the most significant attenuation of GETV virulence. Pathogenicity of N-linked glycosylation mutants in sucking mice. (A) three-day-old suckling mice (n = 8 per group) were inoculated subcutaneously with 106 TCID50 of WT-GETV or glycosylation mutants. Tissues (brain, heart, kidney, Hind limb) were harvested at 2 dpi for analysis; weight and survival were monitored for 10 days. (B) Daily body weight changes. (C) Survival curves. (D-G) Viral RNA loads in indicated tissues quantified by RT-qPCR at 2 dpi. Statistical significance was determined by Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Impact of envelope protein N-linked glycosylation on the protective immunity induced by GETV To determine whether glycosylation of viral envelope proteins influences the induction of neutralizing antibodies and GETV-specific IgG, 3-week-old mice were immunized subcutaneously with 105 TCID50 of WT-GETV or glycosylation mutants, as shown in Figure 6(A). Compared with mice infected with WT GETV, mice infected with the glycosylation site mutants showed reduced viremia, and the titers of the GETV (E1-N141A) and GETV (E2-N200A/N262A) mutants in the mice sera were significantly reduced Figure 6(B). Notably, at 14 and 28 dpi, the GETV (E1-N141A) mutant and GETV (E2-N200A/N262A) mutant were able to elicit to produce higher neutralizing antibody titers and GETV-specific IgG levels than the WT-GETV Figure 6(C–D). To assess protective efficacy, immunized mice were challenged with a high dose of WT-GETV. The results showed that despite variations in neutralizing antibody levels across groups, all glycosylation mutants conferred full protection against GETV challenge Figure 6(E). To investigate whether N-linked glycans effectively shield neutralizing epitopes, 3-week-old mice were immunized subcutaneously with 105 TCID50 of deglycosylated GETV. The neutralizing activity of the sera against wild-type and mutant viruses was assessed at 14 dpi. It was found that the antibodies induced by the deglycosylated virus exhibited better neutralizing activity against the GETV (E1-N141A) mutant and the GETV (E2-N200A/N262A) mutant than against the WT-GETV Figure 6(F). In summary, the GETV (E1-N141A) and GETV (E2-N200A/N262A) mutant induced stronger neutralizing antibody responses than WT-GETV, highlighting their potential as optimized candidates for vaccine development. Impact of envelope protein N-linked glycosylation on GETV-induced protective immunity. (A) Schematic description of the experiment. Three-week-old ICR mice (n = 6 per group) were primed by inoculated subcutaneously injection with 105 TCID50 of WT or mutant GETV. Sera were collected at 1, 2, 14, and 28 dpi. Mice were then challenged with 106 TCID50 of WT-GETV at 30 dpi, and sera were collected at 31 and 32 dpi. (B) Viremia level in serum was determined by TCID50 assay at 1 and 2 dpi. (C, D) Humoral immune responses: serum neutralizing antibody titers (C) and GETV-specific IgG levels (OD450) (D) Measured at 14 and 28 dpi. (E) The mice were re-infected with WT-GETV, viral titres in the serum of all mice at 31 and 32 dpi were determined by TCID50 assay. (F) The titer of neutralizing antibodies induced in mice after immunization with deglycosylated GETV. Statistical significance was determined by Student’s t-test. **p < 0.01, ***p < 0.001 and ****p < 0.0001. Discussion As an emerging alphavirus capable of infecting pigs [10], GETV poses a serious threat to the pig farming industry and public health security. Therefore, it is of great significance to explore protective strategies against GETV. In this study, we have clarified the critical role of specific N-linked glycosylation sites on GETV envelope proteins in the viral replication cycle, pathogenicity, and immunogenicity. Our findings not only confirm that glycosylation is important for GETV replication, but also reveal the distinct functions of different glycosylation sites at the viral life cycle. Tunicamycin, a potent N-linked glycosylation inhibitor, blocks glycoprotein synthesis by inhibiting the transfer of N-acetylglucosamine-1-phosphate to dolichol monophosphate. Among various coronaviruses and influenza viruses, Tunicamycin inhibits viral replication by interfering with the glycosylation modification of viral membrane proteins [23–25]. Similarly, our study demonstrated that tunicamycin treatment significantly suppressed GETV replication in ST cells in a dose-dependent manner (Figure 1). By inhibiting the host cell N-glycosylation pathway, tunicamycin disrupts glycosylation modification of viral envelope proteins within cells, impairing their proper folding and stability. These results also suggest that the host’s glycosylation machinery is indispensable for GETV replication, providing a new direction for the study of the interaction between GETV and host proteins. Due to the diversity of the mechanisms for protein glycosylation, N-linked glycosylation of viral envelope proteins can result in different types of glycan structures [26]. Through analysis of the glycan types on GETV envelope proteins, we confirmed for the first time that both E1 and E2 proteins are modified with complex-type N-linked glycans in ST cells (Figure 2). Similar glycan types have been reported for N-linked glycosylation in the other alphaviruses such as SINV and CHIKV [27]. In contrast, the other mosquito-borne viruses such as flaviviruses primarily carry high-mannose-type glycans [28,29]. Complex-type glycans typically involve more intricate processing steps, which may influence protein intracellular trafficking, conformational stability, and specificity of interactions with host receptors. Furthermore, viral particles with removed surface glycans showed significantly reduced adsorption and entry capabilities, possibly because glycans act as “molecular grips” during infection, facilitating viral adhesion to the cell surface. The marked decrease in infectivity of deglycosylated virions directly demonstrates the importance of these glycan structures for GETV adsorption and internalization. Sequence alignment of multiple GETV strains revealed that the predicted glycosylation sites are highly conserved, underscoring their potential importance in GETV replication. By individually mutating the three predicted N-linked glycosylation sites and generating double mutants, we successfully rescued four GETV glycosylation site mutants. In contrast, the mutation of the glycosylation sites on the SVA E1 envelope protein results in the complete inactivation of the virus [18]. Although all the mutant viruses maintained genetic stability during the transmission process, the replication efficiency and virulence of different variants varied. This indicates that different glycosylation sites may play multiple roles in the virus replication cycle. Among them, glycosylation at the E2-N262 site was crucial for efficient viral adsorption, as its loss severely impaired both early steps. Glycosylation at the E1-N141 site primarily influenced the viral internalization step. A study demonstrated, through structural modeling and SPR experiments, that glycosylation alters the interaction between the virus and its host. Compared with the wild-type virus, both the E1-N141A and E2-N262A N-linked glycosylation mutants exhibited reduced binding reactivity and lower affinity toward the GETV receptors MXRA8 and LDLR [30]. Alternatively, N-linked glycans on the virus may be recognized by C-type lectins (such as DC-SIGN and L-SIGN) on the host cell surface, thereby bypassing the conventional receptor-dependent pathway and entering cells via receptor-mediated endocytosis. During alphavirus infection, the virus enters cells through clathrin-mediated endocytosis upon receptor binding. Subsequently, endosomal acidification triggers conformational rearrangements of E1 and E2, exposing the fusion peptide and mediating membrane fusion. Loss of glycans may disrupt the interaction interface between E1 and E2, affecting the efficiency of E1 trimer formation after acidification and thus interfering with viral entry. For example, the cells expressing DC-SIGN or L-SIGN exhibit markedly enhanced infection by SINV, and this enhancement can be blocked by yeast mannan or EDTA [31]. These findings suggest that this site may play a role in mediating membrane fusion or specific receptor binding. However, previous studies have only provided possible structural hypotheses, and the exact structure or mechanism remains unclear, warranting further investigation. Interestingly, mutation at the E2-N200 site did not impair viral adsorption or entry but significantly compromised the production of infectious progeny virions, despite intracellular RNA replication levels remaining largely unaffected. This may be due to reduced protein stability caused by glycan loss, leading to instability of viral particles during secretion, or impaired protein folding and assembly, resulting in an increased proportion of noninfectious virions and a marked reduction in viral titers in the supernatant. The GETV (E2-N200A/N262A) double mutant exhibited internalization efficiency similar to the WT-GETV. Simultaneous removal of both glycans (N200 and N262) may induce a compensatory conformational change in the E2 protein, thereby restoring the structure required for efficient entry, whereas the loss of a single glycan creates an asymmetric defect that cannot be compensated. For example, deletion of the highly conserved N-linked glycan at Asn260 of the HIV-1 gp120 protein severely impairs viral infectivity. In the search for compensatory mutations, researchers found that the S128N mutation in the V1/V2 loop of gp120 could partially restore the infectivity of the N260Q mutant virus [32]. This possibly reflecting complex conformational compensation or synergistic effects between the two glycosylation sites. This mechanism warranting further investigation. In contrast, the study found that removal of E2-N262 or E1-N141 actually enhanced replication [30]. We propose that the following three factors may account for this discrepancy. First, differences in cell lines and experimental conditions: Ren et al. used BHK-21 and Vero cells for replication assays, whereas we used ST cell. Different cell types may possess distinct glycosylation capacities and endocytic pathways, potentially influencing the effects of glycan loss. Second, the mutagenesis strategy may also affect viral replication. We replaced asparagine with alanine (N→A), whereas other study used an N→Q mutation. Alanine substitution more completely removes the side chain, whereas glutamine partially mimics the amide group and may retain some residual function. Finally, the GETV strains used may differ in their genetic background. Studies on RRV, which also belongs to the Alphavirus genus, have shown that the absence of the E2-200 glycan leads to a significant reduction in RRV replication capacity, whereas the loss of E1 and E2-262 glycans has minimal impact on viral replication [33]. Although GETV and RRV belong to the same genus (Alphavirus), the mutations in the glycosylation sites of their envelope proteins have different effects on the virulence of the viruses. This might be due to the significant differences in the genomic sequences and protein structures of the two viruses. In animal models, our results indicated that glycosylation-targeted mutations effectively attenuated GETV virulence. The E1-N141 mutant and E2-N200 mutant exhibited strong attenuation in a suckling mouse model, with significantly improved survival rates and markedly reduced viral loads in various tissues. Furthermore, we have found that the in vitro replication ability of the mutant virus is not always positively correlated with the clinical symptoms it causes. Although the mutation at the E2-N262 site impairs viral adsorption, it does not markedly attenuate virulence and improve survival rate. This might be due to the pathogenicity of the mutated virus is also related to the internal microenvironment or tissue specificity. Collectively, these findings suggest that the E1-N141 site and E2-N200 are crucial for viral pathogenicity. Most notably, the E1-N141A and E2-N200A/N262A mutants elicited higher levels of neutralizing antibodies than the WT-GETV. Despite their low replication in vivo, both mutants conferred complete protection against WT-GETV. Furthermore, when we used deglycosylated viruses to immunize mice, the antibodies produced by them showed a higher neutralization titer against the mutant virus. This phenomenon may be related to partial removal of the glycan shield, exposing previously masked conserved antigenic epitopes and thereby triggering a stronger and more effective antibody response. These mutants achieved significant attenuation while retaining strong immunogenicity, suggesting their potential as candidate live attenuated vaccines. In summary, this study systematically reveals the role of N-linked glycosylation in GETV replication and pathogenesis, and explored its impact on the induction of neutralizing antibodies in the host by GETV. Our findings enhance the understanding of alphavirus pathogenic mechanisms and provide a novel target for anti-GETV strategies and vaccine design. Supplementary Material Supplementary figure legends.docx Supplemental3 Table S.docx FigS2.tif FigS1.tif Acknowledgements ZC and CM conceived and designed the experiments; HM, TW and YH performed the experiments; HM and CM analyzed the data; HM wrote the manuscript, and then ZC revised the manuscript. All authors read and approved the final manuscript. Funding Statement This work was funded by the 111 Project D18007 and the Priority Academic Program Development of Jiangsu Higher Education Institutions [PAPD] to ZC. It was also supported by the Postgraduate Research & Practice Innovation Program of Jiangsu Province [grant number SJCX24_2306] to HM and Undergraduate Innovation and Entrepreneurship Training Program Project [grant number C202511117008Y] to TW. Disclosure statement No potential conflict of interest was reported by the author(s). Data availability statement The raw data and author checklist of this study are available at https://doi.org/10.17632/54g6zwmtcm.3 . Ethics statement The 3-day-old suckling mice and 3-week-old mice were purchased from Experimental Animal Center of Yangzhou University (Yangzhou, China). All animal experiments were performed in strict compliance with the Guidelines of Laboratory Animal Welfare and Ethics of Jiangsu Administrative Committee for Laboratory Animal, and were approved by the Experimental Animal Ethics Committee of Yangzhou University (approval number: 202,602,033 and 202,606,078). Animals were euthanized under excess isoflurane anesthesia according to the institutional guidelines. All efforts were made to minimize suffering. In this study, we have adhered to ARRIVE guidelines and uploaded a completed checklist as supplementary files. Supplemental data Supplemental data for this article can be accessed online at https://doi.org/10.1080/21505594.2026.2722513 References Associated Data Supplementary Materials Supplementary figure legends.docx Supplemental3 Table S.docx FigS2.tif FigS1.tif Data Availability Statement The raw data and author checklist of this study are available at https://doi.org/10.17632/54g6zwmtcm.3 .